Beta-lactam and Beta-lactamase Inhibitors Market
At an estimatedvalue of over 27.49 billion USD in 2019, the global Beta-lactam and Beta-lactamase Inhibitors Market is predicted tothrive at a CAGR of 1.9% and valued at over USD 34.20 billion over the forecastyear 2020-2030.
Beta-lactaminhibitors fall under a class of antibiotics that consists of all antibioticagents that have a beta lactam ring embedded in their molecular structure.These antibiotic agents helps fight against bacterial infections and protozoainfections. The antibiotic agent either completely kills the bacteria orprevents it from growing and expanding. Names of some beta-lactam antibioticsare penicillin, cephalosporin and many others. On the other hand,beta-lactamase inhibitors are a class of drugs that block the activity ofbeta-lactamase enzymes and restricts the degradation of beta-lactam.Beta-lactamase enzymes are created either constitutively or on exposure toantimicrobials.
Access Full Description of this report at:-
Top Companies: Abbott Laboratories, Allergan plc. F.Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Merck & Co. Inc. Mylan N.V.,Novartis International AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industriesand others.
The globalbeta-lactam and beta-lactamase inhibitors market share has been segmented onthe basis of drug class, disease, route of administration and geography. On thebasis of drug class, the market is categorized into Penicillin, Cephalosporin,Carbapanem, Monobactam and combination. Combination is sub segmented intoPenicillin/Beta Lactamase inhibitors, Cephalosprin/Beta Lactamase inhibitorsand Carbapanem/Beta inhibitors. On the basis of disease, the market issegmented into Urinary Tract Infection (excluding cUTI), Respiratory Infection,Skin Infection, Complicated Urinary Tract Infection (cUTI), ComplicatedIntra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infectionand others. Nosocomial Pneumonia is sub segmented into Hospital AcquiredPneumonia, Ventilator Associated Pneumonia and other. Based on route ofadministration, the market is segmented into oral, intravenous and others. Interms of geography, the market is categorized into North America, Europe, AsiaPacific and RoW.
Request sample copy ofthis report at:-
The North Americaregion is anticipated to hold the major market share as a result of advancedhealth care facilities and infrastructure in conjunction with rise inacceptance of beta-lactam and beta-lactamase inhibitors. The Asia Pacificregion is predicted to show rapid and consistent growth in market share withinthe forecast period. This region also indicates increased prevalence ofinfectious diseases in addition to rise in consumption of such drugs, whichalso serves as favorable factor for the beta-lactam and beta-lactamaseinhibitor market.
About Next Move Strategy Consulting:
Next Move Strategy Consulting is an independent andtrusted third-platform market intelligence provider, committed to deliver highquality, market research reports that help multinational companies to triumphover their competitions and increase industry footprint by capturing greatermarket share. Our research model is a unique collaboration of primary research,secondary research, data mining and data analytics.
We have been servicing over 1000 customers globallythat includes 90% of the Fortune 500 companies over a decade. Our analysts areconstantly tracking various high growth markets and identifying hiddenopportunities in each sector or the industry. We provide one of the industry’sbest quality syndicate as well as custom research reports across 10 differentindustry verticals. We are committed to deliver high quality research solutionsin accordance to your business needs. Our industry standard delivery solutionthat ranges from the pre consultation to after-sales services, provide anexcellent client experience and ensure right strategic decision making forbusinesses.
Formore insights, please visit, https://www.nextmsc.com